NCT03311958View on ClinicalTrials.gov

Molecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 15, 2018

Primary Completion Date

January 26, 2024

Study Completion Date

January 26, 2024

Conditions
Diffuse Large B Cell Lymphoma
Interventions
DRUG

Nivolumab, IV, 240 mg

Patients would be given an infusion of 240 mg nivolumab over 30 min

Trial Locations (1)

19111

Fox Chase Cancer Center, Philadelphia

All Listed Sponsors
lead

Fox Chase Cancer Center

OTHER

NCT03311958 - Molecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance | Biotech Hunter | Biotech Hunter